Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

被引:5
|
作者
Fang, Rui [1 ,2 ]
Wang, Heng [1 ,2 ]
Li, Yang [1 ,2 ]
Liu, Yue-Ming [1 ,2 ]
Wei, Wen-Bin [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Beijing Tongren Hosp, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing 100730, Peoples R China
[3] Beijing Tongren Eye Ctr, Beijing, Peoples R China
[4] Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China
[5] Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China
[6] Minist Ind & Informat Technol, Med Artificial Intelligence Res & Verificat Lab, Beijing, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Uveal melanoma; Plaque radiotherapy; Tumor regression; Prognosis; CHOROIDAL MELANOMAS;
D O I
10.1186/s12886-021-01898-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. Methods Adult uveal melanoma patients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. Results A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). Conclusion Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Perioperative management of a lactating cancer patient undergoing surgical placement and removal of an Iodine-125 brachytherapy plaque for uveal melanoma
    Rieth, Elizabeth
    Barnett, Kara
    Simon, Jennifer
    ANESTHESIA AND ANALGESIA, 2021, 133 (3S_SUPPL): : 1448 - 1448
  • [22] Silicone Oil and Iodine-125 Brachytherapy for Uveal Melanoma in High-Risk Patients
    Lyons, Lance J.
    Hinds, Ethan D.
    Chexal, Sarada
    Berger, Brian
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)
  • [23] Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients
    King, Benjamin A.
    Awh, Caroline
    Gao, Brad T.
    Wang, Jiajing
    Kocak, Mehmet
    Morales-Tirado, Vanessa M.
    Ballo, Matthew T.
    Wilson, Matthew W.
    OCULAR ONCOLOGY AND PATHOLOGY, 2019, 5 (05) : 340 - 349
  • [24] Expansion and regression of prostate volume after permanent brachytherapy with iodine-125
    Messer, PM
    Goufried, HW
    Schneider, E
    Waletzko, O
    Hautmann, R
    Röttinger, EM
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 : 42 - 42
  • [26] Intra-operative ocular ultrasonography of iodine-125 brachytherapy plaques in patients with uveal melanoma
    Pineiro Ces, Antonio
    Bande Rodriguez, Manuel
    Mosquero Sueiro, Javier
    Carballo Castro, Ana Maria
    Lobato Busto, Ramon
    Silva Rodriguez, Paula
    Pardo Perez, Maria
    Ruiz Oliva-Ruiz, Francisco
    Blanco Teijeiro, Maria Jose
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2021, 13 (02) : 126 - 134
  • [27] Enucleation After Iodine-125 Plaque Brachytherapy in Patients with Large Choroidal Melanomas
    Tse, Brian
    Shildkrot, Yevgeniy
    Wilson, Matthew W.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [28] A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma
    Miguel, David
    de Frutos, Jesus Maria
    Alonso, Pilar
    Garcia-Alvarez, Ciro
    Saornil, Maria Antonia
    Diezhandino, Patricia
    Garavis, Maria Isabel
    Valencia, Patricia
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2023, 15 (05) : 350 - 356
  • [29] Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
    Miguel, David
    Saornil, Maria Antonia
    de Frutos, Jesus Maria
    Garcia-Alvarez, Ciro
    Alonso, Pilar
    Diezhandino, Patricia
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2021, 13 (02) : 117 - 125
  • [30] Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread
    Pepin, Francois
    Julien, Anne-Sophie
    Fugaru, Ioana
    Lihimdi, Nadia
    Thariat, Juliette
    Landreville, Solange
    Mouriaux, Frederic
    MELANOMA RESEARCH, 2019, 29 (03) : 295 - 300